Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Durect Corporation currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units, indicating a broad spread of current prosecution activity. This diversification suggests that the corporation's patent applications are being reviewed by different technical specialists across multiple departments at the patent office.
BORALSKY, LUKE ALAN is the busiest examiner, holding 1 pending office action. With 3 pending office actions and 3 distinct examiners, each examiner is responsible for 1 action. This distribution across 3 distinct art units suggests that the corporation's current patent matters are being reviewed by separate technical specialists. For the practitioner, this means that each of the 3 pending office actions requires a unique approach tailored to the specific examiner and the standards of their respective art unit, as there is no central point of review for the current portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924103 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924101 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | NOTTINGHAM, KYLE GREGORY | 21d |
| 18572715 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | BORALSKY, LUKE ALAN | — |
| 17924103 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572715 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 17924103 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | VALLE, ERNESTO | 1623 | §103§112Other | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17924101 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | NOTTINGHAM, KYLE GREGORY | 1621 | §103§112DP | Non-Final OA | 21d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial